Scientific deep-dive
GLP-1 Side Effects Duration: Fatigue, Hair Loss, and How Long Everything Actually Lasts
Most GLP-1 nausea fades within 1 to 2 weeks at each dose step, peaking in the first 1 to 2 weeks after an increase. Fatigue was reported by about 11% on semaglutide versus 5% on placebo in the Wegovy label's pooled STEP 1-3 data. This guide covers how long fatigue, hair loss, and GI effects last.
Our broader GLP-1 side effects investigation covers the headline adverse-event rates from the STEP and SURMOUNT trials. This article answers a different and more common question: how long do the side effects actually last? Three specific concerns come up most often (fatigue, hair loss, and the duration of the standard GI side effects), and the trial data is much more specific than most patients realize. We walk through each one with the verified numbers from the STEP-1 and SURMOUNT-1 prescribing information tables [1, 2, 3, 4] and the published clinical practice guidance on side-effect management [5, 6].
How long do the GI side effects last?
The classic GLP-1 side effects are gastrointestinal — nausea, vomiting, diarrhea, constipation, abdominal pain. The STEP-1 and SURMOUNT-1 trial publications don't report duration directly in the headline tables, but the timing pattern is consistent across both trials and across subsequent clinical practice reviews [5]:
- Onset: within hours to 2-3 days of the first injection, and within hours of each subsequent dose escalation.
- Peak intensity: first 1-2 weeks after any dose increase. The starter dose (0.25 mg semaglutide, 2.5 mg tirzepatide) is tolerated by most patients; the first two escalations (to 0.5 mg and 1.0 mg semaglutide; to 5 mg and 7.5 mg tirzepatide) tend to produce the strongest GI symptoms.
- Resolution: most patients report that nausea from any given dose step subsides within 1-2 weeks of continued dosing at that level. By the time the next escalation is due (end of week 4), most patients are back to baseline GI tolerance and the cycle repeats.
- Late course: by the time the maintenance dose is reached (week 16-20 on the standard ramp), roughly 50-60% of patients report no ongoing GI symptoms [5]. The remaining 40-50% have mild residual effects that persist at a stable level.
The Wharton 2022 clinical practice review on GI side effect management [5] documents that the standard trial-reported rates in STEP-1 (for nausea, ~44% at some point during the trial) substantially overstate the fraction of patients who have ongoing nausea at any given week — most nausea is peri-titration and transient.
Does semaglutide (or tirzepatide) make you tired?
“Does semaglutide make you tired?” is one of the most common GLP-1 side-effect questions. The direct answer from the FDA prescribing information tables is: yes, fatigue is a reported adverse event, but at a meaningfully lower rate than the GI symptoms.
Specific reported rates from the STEP-1 and Wegovy label adverse reactions table [1, 3]:
- Fatigue: reported in ~11% of Wegovy-treated patients vs ~5% of placebo (STEP 1-3 pooled, label), over up to 68 weeks
From the SURMOUNT-1 and Zepbound label [2, 4]:
- Fatigue: ~5-7% across the Zepbound 5, 10 and 15 mg arms vs ~3% on placebo (label pool of SURMOUNT-1 and SURMOUNT-2)
Fatigue is real, documented, and modestly more common on GLP-1 therapy than on placebo. But the attribution is complicated: rapid weight loss by any mechanism is associated with fatigue, and GLP-1 patients by definition lose weight rapidly. It's difficult to separate drug-specific fatigue from the fatigue of a reduced-calorie week with 10-15% more weight loss than placebo.
Why fatigue happens on GLP-1s
- Caloric deficit. The whole point of the drug is to reduce caloric intake, and the body responds to a 500-1000 kcal/day deficit with predictable fatigue during the first few weeks of any such deficit, regardless of the mechanism producing it.
- Reduced protein intake. When appetite drops, protein intake usually drops disproportionately because high-protein foods (eggs, meat, Greek yogurt) are more filling and patients can't eat as much of them. Low protein intake worsens fatigue and also accelerates lean mass loss — see our semaglutide and muscle mass deep-dive for the protein targets.
- Dehydration. GLP-1 patients commonly under-drink water because thirst and appetite signals are both blunted. Mild chronic dehydration is a major fatigue contributor and a fixable one.
- Transient nausea-induced reduced sleep. Nausea that wakes a patient at night (especially in the first 1-2 weeks of each dose step) produces sleep fragmentation and next-day fatigue.
- Vitamin deficiency. Reduced overall intake over months can produce B-vitamin, iron, and vitamin D deficiencies that all manifest as fatigue. Labwork is the quickest way to screen.
When fatigue should prompt medical attention
- Fatigue accompanied by dizziness, fainting, or persistent lightheadedness — possible dehydration or blood pressure drop.
- Fatigue accompanied by dark urine, reduced urine output, or abdominal pain — rule out dehydration-induced kidney injury (a documented GLP-1 concern, see Wegovy label warnings).
- Fatigue that doesn't improve after 4-6 weeks of dose stability and corrected protein + hydration.
- Fatigue with new shortness of breath — rule out cardiac or anemia causes unrelated to the GLP-1.
Does semaglutide or tirzepatide cause hair loss?
“Does tirzepatide cause hair loss?” is one of the most common GLP-1 questions. The answer from the trial data is specific and worth understanding. For the Ozempic-specific framing of this same syndrome and the full telogen-effluvium mechanism behind it, see our deep-dive on Ozempic hair loss + telogen effluvium evidence.
Hair loss rates reported in the FDA prescribing information adverse reactions tables [3, 4]:
- Wegovy (STEP 1-3 pooled, label): alopecia reported in ~3% of semaglutide-treated patients vs ~1% of placebo.
- Zepbound (SURMOUNT-1 and -2 pooled, label): alopecia reported in ~4-5% of tirzepatide-treated patients vs ~1% of placebo.
Tirzepatide has a numerically higher rate than semaglutide, possibly reflecting the larger average weight loss in SURMOUNT-1 (~21%) vs STEP-1 (~15%). The important context: these rates are almost certainly driven by the weight loss itself rather than any drug-specific mechanism.
Magnitude comparison
Alopecia (hair shedding) and fatigue rates from the FDA prescribing information adverse-reactions tables — Wegovy (STEP 1-3 pooled, up to 68 wk) and Zepbound (SURMOUNT-1 and -2 pooled) vs placebo.[1][2][3][4]
- Alopecia — placebo (Wegovy and Zepbound label pools)1 %background rate without GLP-1 therapy
- Alopecia — Wegovy (semaglutide 2.4 mg)3 %
- Alopecia — Zepbound (tirzepatide 15 mg)5 %
- Fatigue — placebo (Wegovy label pool)5 %calorie-deficit fatigue without active drug
- Fatigue — Wegovy (semaglutide 2.4 mg)11 %
- Fatigue — Zepbound (tirzepatide 15 mg)7 %5–7% across the 5, 10 and 15 mg arms vs 3% placebo (SURMOUNT-1 and -2 pooled)
Telogen effluvium — the mechanism
The hair loss pattern that patients report on GLP-1s is classic telogen effluvium — a reversible shedding phase triggered by physiological stress, and crash dieting, low protein intake and iron deficiency are among its documented triggers [6]. The pattern:
- Onset at 2-4 months after starting rapid weight loss. The hair follicles take 2-4 months to transition from growth phase to shedding phase after a triggering stress, so patients typically don't notice hair loss until they're already several months into GLP-1 therapy.
- Diffuse thinning, not patchy. Telogen effluvium produces widespread thinning across the whole scalp, not bald patches. If you have bald patches, see a dermatologist — it's a different condition.
- Shed lasts 3-6 months, then resolves. Once the triggering stress (rapid weight loss) stabilizes, the hair follicles cycle back into growth phase and the shed resolves.
- No permanent damage. Telogen effluvium is reversible. It does not cause permanent hair loss and it does not require stopping the medication to resolve.
What to do if you're losing hair on a GLP-1
- Confirm protein intake is adequate (1.2-1.6 g/kg of lean body mass per day). Low protein intake is the most-studied reversible contributor to diet-associated telogen effluvium.
- Check iron and ferritin. Iron deficiency without anemia is a common hair-loss amplifier in women on rapid-weight-loss diets. A simple CBC + ferritin blood test screens for it.
- Check vitamin D and B12. Both are associated with telogen effluvium when deficient.
- Wait. If labs are normal and protein is adequate, the condition is self-limited and the shedding settles once your weight stabilizes. You do not need to stop the GLP-1 to recover.
- See a dermatologist if the shedding is patchy, if it lasts longer than 9 months without improvement, or if you notice scalp irritation. Minoxidil is not typically needed for telogen effluvium but can accelerate regrowth in motivated patients.
Duration reference table
Combining the STEP-1, SURMOUNT-1, Wegovy label, and Zepbound label data, here's a single-page reference for how long each major GLP-1 side effect typically lasts:
| Side effect | Typical onset | Typical duration | Resolves on its own? |
|---|---|---|---|
| Nausea | Days 1-3 of each dose step | 1-2 weeks per step; <50% of patients by maintenance | Yes, as body adapts |
| Vomiting | Days 1-7 of early dose steps | 1-2 weeks; rare after week 16 | Yes, if nausea resolves |
| Diarrhea | Days 1-7 of dose steps | Intermittent; improves after maintenance reached | Usually yes |
| Constipation | Weeks 2-4 of therapy | May persist longer; manageable with fiber/water | Usually with intervention |
| Fatigue | Weeks 1-8 of therapy | Weeks to months; improves with protein/hydration correction | Usually yes, with support |
| Hair loss (telogen effluvium) | Months 2-4 after starting rapid loss | 3-6 months of shedding, then resolves | Yes — reversible, 6-12 months post- stabilization |
| Abdominal pain | Peri-titration | Days to 1-2 weeks per step | Yes; call if severe or persistent |
| Injection site reaction | Within 24-48 hours of injection | 1-3 days per injection | Yes |
Red-flag symptoms that require medical attention
Most GLP-1 side effects are self-limiting and managed by dose-level adjustment, slower titration, and protein/hydration support. The following symptoms are different — they indicate potentially serious complications documented in the Wegovy and Zepbound labels [3, 4] and should prompt a call to your prescriber or ER visit:
- Severe abdominal pain radiating to the back (possible pancreatitis — stop the drug, go to ER)
- Yellowing of skin or eyes (gallbladder disease — evaluate urgently)
- Severe or persistent vomiting with dark urine or reduced urine output (dehydration, potential kidney injury)
- Signs of severe allergic reaction (swelling of face/throat, difficulty breathing, severe rash) — stop and go to ER immediately
- Visual changes in patients with type 2 diabetes (possible diabetic retinopathy progression)
- Neck lump, hoarseness, or difficulty swallowing — evaluate urgently (rare thyroid C-cell concern, label warning)
For the broader side effect rate data, see our GLP-1 side effects investigation. For the onset and time-to-work curves that determine when each side effect peaks, see our how long does GLP-1 take to work guide. For the lean-mass preservation protein targets, see our semaglutide and muscle mass deep-dive. For injection site reactions and rotation technique, see our where to inject guide. For the dose plotter that visualizes how titration timing interacts with side-effect cycles, see our dose plotter.
Further reading
- Top semaglutide side-effect questions on Reddit, answered
- Top tirzepatide questions on Reddit, answered
- Top GLP-1 hair-loss questions on Reddit, answered
- GLP-1 sick-day guide cheat sheet
Frequently Asked Questions
References
- 1.Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF; STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021. PMID: 33567185.
- 2.Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A; SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022. PMID: 35658024.
- 3.Novo Nordisk Inc. WEGOVY (semaglutide) injection — US Prescribing Information, Section 6: Adverse Reactions. FDA Approved Labeling. 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215256s024lbl.pdf
- 4.Eli Lilly and Company. ZEPBOUND (tirzepatide) injection — US Prescribing Information, Section 6: Adverse Reactions. FDA Approved Labeling. 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/217806s016lbl.pdf
- 5.Wharton S, Davies M, Dicker D, Lingvay I, Mosenzon O, Rubino DM, Pedersen SD. Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice. Postgraduate Medicine. 2022. PMID: 34775881.
- 6.Hughes EC, Syed HA, Saleh D. Telogen Effluvium. StatPearls (StatPearls Publishing). 2024. PMID: 28613598.
Related research
Ozempic Fatigue: Why Semaglutide Can Make You Tired & What to Do (2026)
Is fatigue an Ozempic side effect? Yes — fatigue and asthenia are labeled for semaglutide. Why it happens (under-eating, dehydration, low blood sugar), when tiredness is a red flag, and prescriber-directed ways to manage it. Verified against the FDA DailyMed labels.
9 min read
Ozempic Flu: Why You Get Flu-Like Symptoms on a GLP-1 (and What Helps)
"Ozempic flu" is the cluster of flu-like symptoms some people get starting a GLP-1 or after a dose increase. The honest mechanism, what helps, and sick-day rules.
8 min read
Does NAD+ Boost Energy? What the Evidence Says (and GLP-1 Fatigue)
NAD+ precursors (NMN, NR) raise NAD+ in blood and muscle but human RCTs have not shown improved energy or fatigue. IV drips have no controlled trials.
12 min read
Do GLP-1s Cause Hair Loss? What All 5 Labels Say (2026)
Wegovy and Zepbound list hair loss in 3–6% of adults vs 1% on placebo; Ozempic, Rybelsus and Mounjaro give no rate. Why it happens and what helps.
8 min read
Does Mounjaro Cause Hair Loss? What the FDA Label Says (2026)
Mounjaro lists alopecia only as a postmarketing report, with no SURPASS trial rate. Why Zepbound's 5% doesn't transfer, and what to do about shedding.
10 min read
Does Wegovy Cause Hair Loss? What the FDA Label Says (2026)
Wegovy's label: hair loss in 3.3% on 2.4 mg vs 1% on placebo (4% of women, 0.9% of men), 5.8% on 7.2 mg. When shedding starts and what helps.
11 min read
Where to get GLP-1 safely: vetted online providers
Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.
No insurance needed · vetted by our editors
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money
Oak
Compounded semaglutide and tirzepatide at a low starting price, with a full price list before you sign up
Read full review →Pricing Compare
Get started →Pricing Compare
Get started →Pricing Compare
Get started →